at it's finest.
We have the capacity to rapidly become globally the largest producer of organic therapy mushrooms, with significant opportunity for local and international growth.
We are in the process of securing a 23,000 sq. ft. growing facility exclusively designed for PsiloTec’s needs.
All production will be carried out under the highest
GMP quality standards.
Mycology expertise augmented by laboratory agreements
to analyze PsiloTec mushroom genetics.
Exclusively licensed IP to enhance yields
and speed of harvest.
Unique strains of mushrooms secured along with ongoing research and development of new IP
Anticipated production of psilocybin for clinical trials beginning Q2, 2021, at partnered sites.
Estimated production commencing in Alberta in Q4, 2021.
Mycology Product Development
We will also be developing a range of boutique mushrooms in
which multiple neuroactive products will be captured,
including psilocybin, psilocin, baeocystin, and norbaeocystin.
These will allow these boutique mushrooms to offer unique, and IP-protected, treatment opportunities.
The easiest product to produce is dried mushrooms containing mostly psilocybin. Our goal is to
become the lowest cost provider for this.
Products to be developed over the next 2 – 3 years
will also include combination products.
Products will also increasingly utilize unique,
and IP-protected, delivery mechanisms.
All products will have rigorous batch and genetic
controls to allow reliable scalability to meet
whatever needs the market requires.